Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to receive our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

Background: Immune-targeted therapies are being successfully implemented into cancer clinical practice. In particular checkpoint inhibitors are employed to modulate the immune microenvironment of solid tumors. We sought to determine the expression of PD-L1, HVEM, and B7H3 in human and canine ...

Author(s)
Cascio, M. J.; Whitley, E. M.; Sahay, B.; Cortes-Hinojosa, G.; Chang LungJi; Cowart, J.; Salute, M.; Sayour, E.; Dark, M.; Sandoval, Z.; Mitchell, D. A.; Milner, R. J.
Publisher
Elsevier B.V., Amsterdam, Netherlands
Citation
Veterinary Immunology and Immunopathology, 2021, 232,
AbstractFull Text

Canine osteosarcoma is an agressive tumour that has both a locally invasive and highly metastatic biologic behavior. Osteosarcoma is the most important primary bone tumour in dogs, being the most common. Usually, it's occurrence is in the appendicular skeleton and the most frequently involved are...

Author(s)
Alexandru, D. M.; Dobre, I. R.; Crivineanu, M.
Publisher
University of Agronomic Sciences and Veterinary Medicine of Bucharest, Bucharest, Romania
Citation
Scientific Works. Series C. Veterinary Medicine, 2020, 66, 1, pp 25-29
Abstract

Osteosarcoma, a common malignancy in large dog breeds, typically metastasises from long bones to lungs and is usually fatal within 1 to 2 years of diagnosis. Better therapies are needed for canine patients and their human counterparts, a third of whom die within 5 years of diagnosis. We compared...

Author(s)
Patatsos, K.; Shekhar, T. M.; Hawkins, C. J.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 4, pp 544-553
Abstract

Osteosarcoma is the most common paediatric primary bone malignancy. The major cause of death in osteosarcoma is drug-resistant pulmonary metastasis. Previous studies have shown that thioredoxin reductase 2 is a driver of metastasis in osteosarcoma and can be inhibited by auranofin (AF). Moreover,...

Author(s)
Endo-Munoz, L.; Bennett, T. C.; Topkas, E.; Wu, S. Y.; Thamm, D. H.; Brockley, L.; Cooper, M.; Sommerville, S.; Thomson, M.; O'Connell, K.; Lane, A.; Bird, G.; Peaston, A.; Matigian, N.; Straw, R. C.; Saunders, N. A.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2020, 18, 2, pp 206-213
Abstract

To prove that microRNA-133a in the blood of dogs with osteosarcoma can be used as an effective diagnostic tool, 20 dogs were used in this study, 10 dogs had osteosarcomas and the other 10 dogs had neoplasms other than osteosarcoma. After examining blood samples for the animals, higher levels of...

Author(s)
Ikeda, N.; Chiba, S.; Nakagawa, Y.; Hayashi, Y.; Fukushima, R.; Ito, H.; Ucide, T.
Publisher
Buneido Publishing Company Ltd, Tokyo, Japan
Citation
Journal of Veterinary Medicine, Japan, 2018, 71, 7, pp 495
Abstract

Since William Coley utilized bacterial immunotherapy to treat sarcomas in the late 19th century, an association between infection and improved survival has been reported for human and canine osteosarcoma patients. One of the reasons for this improved survival is likely a reactivation of the host...

Author(s)
Tuohy, J. L.; Somarelli, J. A.; Borst, L. B.; Eward, W. C.; Lascelles, D. X.; Fogle, J. E.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2020, 18, 1, pp 64-75
Abstract

The effects of radiation therapy may be potentiated by combining radiation therapy with secondary therapies. Clinically, radiation therapy has been combined with bisphosphonates for treatment of canine appendicular osteosarcoma for years. The objective of this study was to determine if the timing...

Author(s)
Hoddinott, K.; Oblak, M. L.; Wood, G. A.; Boston, S.; Mutsaers, A. J.
Publisher
Canadian Veterinary Medical Association, Ottawa, Canada
Citation
Canadian Journal of Veterinary Research, 2020, 84, 3, pp 225-229
Abstract

Osteosarcoma is an aggressive primary bone tumor in humans and is among the most common cancer afflicting dogs. Despite surgical advancements and intensification of chemo- and targeted therapies, the survival outcome for osteosarcoma patients is, as of yet, suboptimal. The presence of metastatic...

Author(s)
Jyotika Varshney; Scott, M. C.; Largaespada, D. A.; Subbaya Subramanian
Publisher
MDPI AG, Basel, Switzerland
Citation
Veterinary Sciences, 2016, 3, 1, pp 3
Abstract

Osteosarcoma remains the most common primary bone tumour in dogs with half of affected dogs unable to survive 1 year beyond diagnosis. New therapeutic options are needed to improve outcomes for this disease. Recent investigations into potential therapeutic targets have focused on cell surface...

Author(s)
Alegre, F.; Ormonde, A. R.; Godinez, D. R.; Illendula, A.; Bushweller, J. H.; Wittenburg, L. A.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2020, 18, 1, pp 52-63
Abstract

Background: High-dose, pharmacological ascorbate (P-AscH-) is preferentially cytotoxic to human cancer cells in vitro. Investigations on the efficacy of P-AscH- as an adjuvant treatment for multiple human cancers are on-going, but has yet to be formally investigated in dogs. The primary objectives...

Author(s)
Musser, M. L.; Mahaffey, A. L.; Fath, M. A.; Buettner, G. R.; Wagner, B. A.; Schneider, B. K.; Seo YeonJung; Mochel, J. P.; Johannes, C. M.
Publisher
Frontiers Media S.A., Lausanne, Switzerland
Citation
Frontiers in Veterinary Science, 2019, 5, November,

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics

Datasheet Filter

Datasheet Type